## SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

FORM 8-K

### CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): December 5, 2013

<u>OptimizeRx Corporation</u> (Exact name of registrant as specified in its charter)

Nevada 000-53605 26-1265381 (State or other jurisdiction of incorporation) (Commission File Number) (I.R.S. Employer Identification No.)

400 Water Street, Suite 200, Rochester, MI (Address of principal executive offices)

48307 (Zip Code)

Registrant's telephone number, including area code: <u>248-651-6568</u>

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

	Written communications	pursuant to Rule 425 under the	Securities Act (17CFR 230.425)
--	------------------------	--------------------------------	--------------------------------

- [] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- [] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

### **SECTION 7 – Regulation FD Disclosure**

#### **Item 7.01 Regulation FD Disclosure**

On December 5, 2013, OptimizeRx Corporation (the "Company") made an investor presentation that included the slides furnished as Exhibit 99.1 to this Current Report on Form 8-K. The slides contained in Exhibit 99.1 are also posted on the Company's website at www.optimizerxcorp.com.

The information in Item 7.01 of this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.

#### **SECTION 9 – Financial Statements and Exhibits**

#### **Item 9.01 Financial Statements and Exhibits**

99.1 <u>Investor Relations Presentation, dated December 5, 2013</u>

#### **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

#### **OptimizeRx Corporation**

<u>/s/ David Lester</u>
David Lester
Chief Operating Officer

Date: December 5, 2013



### **OPTIMIZERx Corporation (symbol OPRX)**

### David Harrell, Chairman & CEO H. David Lester, COO

OPTIMIZERx Corporation
400 Water Street, Suite 200
Rochester, MI 48307
Phone: 248.651.6568
Fax: 248.453.5529
http://www.optimizerxcorp.com/

### SAFE HARBOR:

This presentation contains forward-looking statements within the definition of Section 27A of the Securities Act of 1933, as amended and such section 21E of the Securities Act of 1934, amended. These forward-looking statements should not be used to make an investment decision.

The words 'estimate,' 'possible' and 'seeking' and similar expressions identify forward-looking statements, which speak only as to the date the statement was made. The company undertakes no obligation to publicly update or revise any forward-looking statements, whether because of new information, future events, or otherwise.

Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted, or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.




### Pharma eyes EHR for engaging with docs

At a recent MM&M Leadership Exchange, participants were ready to declare that the great digital channel shake-up may have reached its peak...

According to Levy, it may be time for marketers to stop looking at the phone, tablet or "phablet" as the Holy Grail of physician engagement. "Pharma brand managers need to move where their audience does. Their next frontier: the EHR."

"EHRs will become the dominant context for physicians," said Craig DeLarge, global leader, multichannel marketing strategy and innovation, Merck. "We've been slow to internalize the idea and engage in the EHR format."

Because the EHR is the center of physician workflow, accompanying e-prescribing data with the right information should be the new thrust for HCP engagement.











- SampleMD is a software platform that allows pharmaceutical and other interested companies to replace drug samples by automating co-pay savings and sample voucher offers directly in the doctor's electronic prescribing workflow.
- Doctors are able to offer patients sample vouchers or coupons on-site at the time of prescription, making it easy and simple to use.
- Coupon info is printed & automatically sent to pharmacy with eRx
- SampleMD is paid average of \$4-\$5 by the manufacturer each time an eCoupon or eVoucher is automatically <u>distributed</u> to a patient.

# SampleMD is attractive to all stakeholders

- **Pharma:** Provides access to prescribers and patients at the point of prescription, the most critical moment in the prescription chain
- Doctors: Provides information regarding drugs and the financial assistance available to patients, allowing doctors to choose their preferred drug while maintaining adherence
- EHR/EMRs: Provides low-cost incremental revenue for systems already in place

 Patients: Provides overall lower cost of prescriptions, improving adherence and outcomes


> Instant \$15 Savings Coupon On Your 150 mg Prescription!\*


> > Sufficient (business

# Model offers Huge Scalability following just eRx Trends!


Through Major Government Incentives, Healthcare providers have moved to EHRs, with over 80% of them now ePrescribing

By 2016, an estimated 2 billion prescriptions will be electronically sent per year and growing thereafter



















### SampleMD Core eCoupon Business Usage Metrics Jan 2010 –Sept 2013



### **OPRX QUARTERLY REVENUE**



1 Q 2 0 1 0 2 Q 2 0 1 0 3 Q 2 0 1 0 4 Q 2 0 1 0 1 Q 2 0 1 1 2 Q 2 0 1 1 3 Q 2 0 1 1 4 Q 2 0 1 1 1 Q 2 0 1 2 2 Q 2 0 1 2 3 Q 2 0 1 2 4 Q 2 0 1 2 1 Q 2 0 1 2 3 Q 2 0 1 3 4 Q